What's Happening?
Resurrect Bio, a UK-based startup, has raised $8.1 million in a Series A funding round to advance its technology that enhances plants' innate disease resistance. The investment, led by Corteva and supported by other investors, will be used to accelerate product development and expand the team. Resurrect Bio's technology focuses on identifying and modifying the interactions between plant immune receptors and pathogen proteins, thereby preventing diseases without chemical inputs. This approach aims to provide up to 100% resistance to various plant diseases, offering a sustainable alternative to traditional agricultural practices.
Why It's Important?
The development of disease-resistant crops is significant for the agricultural industry, as it addresses the challenges
posed by evolving pathogens that suppress plant defenses. By enhancing plants' natural resistance, Resurrect Bio's technology could reduce the reliance on chemical pesticides, leading to more sustainable farming practices. This innovation has the potential to improve crop yields and food security, benefiting farmers and consumers alike. Additionally, the technology's applicability to multiple crops and pathogens positions it as a versatile solution in the fight against agricultural diseases.
What's Next?
Resurrect Bio plans to continue developing its technology for a range of crops, including soy, corn, and wheat. The company is also working on joint development agreements with seed companies to integrate its disease resistance traits into commercial germplasms. As the technology progresses, Resurrect Bio aims to deliver 18 disease resistance traits in major crops over the next three years, further enhancing its impact on global agriculture.
